modifying the disease process itself
For the millions caught between chronic knee pain and the threshold of surgery, medicine has long offered only partial answers. A study from NYU Langone Health now suggests that a two-hour, minimally invasive procedure — one that redirects blood flow rather than replacing bone — may not only quiet the pain of osteoarthritis but alter the disease's course. It is a small study, and larger trials must follow, but the finding places a new possibility on the map of human aging and its discontents.
- Over 24 million Americans are diagnosed with knee osteoarthritis each year, and many face a painful limbo — too ill to ignore, not yet eligible for joint replacement surgery.
- Genicular artery embolization works by threading a catheter to the knee and releasing tiny beads that cut off the abnormal blood supply feeding inflammation, all within two hours and without an overnight hospital stay.
- In a 25-patient trial, more than 60 percent reported meaningful gains in pain, stiffness, and mobility one full year after the procedure — a durability that caught researchers' attention.
- Blood tests revealed drops in VEGF and IL-1Ra, proteins tied to disease progression, suggesting the procedure may be reshaping the biology of the joint, not merely masking its symptoms.
- Side effects were minor — skin discoloration and mild incision pain — but the study's small scale means larger trials are still needed to confirm who benefits most and for how long.
An interventional radiologist guides a thin catheter through a small thigh incision, navigating by video to the knee, where tiny biocompatible beads are released into the arteries feeding the joint. The procedure takes under two hours. The patient goes home the same day. This is genicular artery embolization — and a new NYU Langone Health study suggests it works.
Osteoarthritis erodes cartilage and inflames the joint, prompting the body to grow new blood vessels that carry immune cells amplifying the damage. The embolization procedure targets this cycle directly, blocking the abnormal blood flow that supplies the synovium — the joint's inner lining — before it can sustain the inflammation.
The study followed 25 patients aged 50 to 78, all with moderate-to-severe osteoarthritis that had resisted corticosteroid injections, fluid drainage, platelet-rich plasma, and physical therapy. One year after the procedure, more than 60 percent reported significant improvements in pain, stiffness, and mobility. The results were published August 12 in the Journal of Vascular Interventional Radiology.
What distinguished the findings was evidence beyond symptom relief. Blood tests showed a 12 percent average drop in VEGF, a protein driving new blood vessel formation, and a 15 percent decline in IL-1Ra, an inflammation-related marker. These objective chemical shifts suggested the procedure may be modifying the disease itself, not merely dulling its effects. Lead investigator Ryan Hickey called it evidence of something more than pain management.
The clinical stakes are considerable. With knee osteoarthritis diagnoses expected to rise alongside an aging population, many patients remain caught between inadequate conservative treatments and a surgery they cannot or will not undergo. Genicular artery embolization offers a third path. Side effects were minor, and no serious complications were reported.
Still, the study's scale demands caution. Larger trials are needed to establish how long the benefits last and which patients are best suited for the procedure. Principal investigator Bedros Taslakian proposed that VEGF levels could serve as a biomarker for gauging success — a measurable signal to complement what patients report. For now, the procedure stands as a proof of concept: a brief intervention that may do more than ease suffering, and may slow the disease itself.
An interventional radiologist threads a thin catheter through a small incision in the thigh, navigates it to the knee under video guidance, and releases tiny biocompatible beads into the arteries feeding the joint. The whole thing takes less than two hours. The patient goes home the same day, sedated but conscious. This is genicular artery embolization, and according to a study published this month by NYU Langone Health, it works.
Osteoarthritis of the knee is a disease of breakdown. The cartilage wears away. The joint becomes inflamed. In response, the body grows new blood vessels—a process called angiogenesis—and blood flow to the joint increases. Those vessels carry immune cells that amplify the inflammation and the pain. The procedure blocks that abnormal blood flow before it can do its damage. The beads lodge in the arteries that feed the synovium, the membrane lining the joint, starving the inflammation of its supply line.
The study followed 25 patients, ranging in age from 50 to 78, all of whom had moderate to severe knee osteoarthritis that had resisted the standard treatments: corticosteroid injections, fluid drainage, platelet-rich plasma injections, and physical therapy. Between January 2021 and January 2023, each underwent the embolization procedure. One year later, more than 60 percent of them reported significant improvements in pain, stiffness, and their ability to move—to bend, to stand, to climb stairs. The results appeared online August 12 in the Journal of Vascular Interventional Radiology.
What makes the finding noteworthy is not just the pain relief. Blood tests revealed that the procedure appeared to alter the disease itself. Levels of vascular endothelial growth factor, or VEGF—a protein that triggers the formation of new blood vessels and has been linked to structural changes in osteoarthritic knees—dropped by an average of 12 percent. Interleukin 1 receptor agonist, a protein that counters inflammation, fell by 15 percent. These are not subjective measures. They are chemical markers in the blood, objective evidence that something in the joint's biology has shifted. "Our study shows that genicular artery embolization is a safe and effective, minimally invasive treatment," said Ryan Hickey, an associate professor of radiology at NYU Grossman School of Medicine and one of the study's lead investigators. "This work also provides evidence that genicular artery embolization is offering more than just pain relief and could be modifying the disease process itself."
The procedure addresses an urgent clinical need. An estimated 24 million cases of knee osteoarthritis are diagnosed each year in the United States, a number expected to climb as the population ages. Many patients are not yet ready for knee replacement surgery, or cannot have it because of age, obesity, uncontrolled diabetes, heart disease, or smoking. They are stuck between pain and the operating room. Genicular artery embolization offers a third path—less invasive than surgery, more targeted than injections.
The side effects were minimal: dark skin discoloration on the knee and mild pain at the incision site. No serious complications were reported. Patients achieved clinically significant pain reduction if they showed at least a four-point improvement on a 20-point pain scale, and the majority crossed that threshold.
Still, questions remain. How long do the benefits last? Which patients are most likely to respond? Larger clinical trials are needed to confirm the durability of the effect and to refine patient selection. Bedros Taslakian, the study's principal investigator, now at the University of Miami, suggested that VEGF levels could serve as an objective biomarker for measuring the procedure's success—a chemical fingerprint that tells doctors whether it worked, rather than relying on what patients report. The NYU Langone team plans to investigate the precise mechanisms by which embolization reduces inflammation and relieves pain. For now, the procedure stands as a proof of concept: a two-hour intervention that may do more than ease suffering—it may slow the disease itself.
Notable Quotes
This work also provides evidence that genicular artery embolization is offering more than just pain relief and could be modifying the disease process itself.— Ryan Hickey, MD, associate professor of radiology at NYU Grossman School of Medicine
Our study findings indicate that genicular artery embolization may slow down the progression of osteoarthritis by observing significant decreases in signaling proteins, specifically vascular endothelial growth factor and interleukin 1 receptor agonist, one year after the procedure.— Bedros Taslakian, MD, principal investigator, University of Miami Miller School of Medicine
The Hearth Conversation Another angle on the story
Why does blocking blood flow to the knee actually help? Doesn't the joint need blood?
It does, but the problem is what that blood is carrying. In osteoarthritis, the body overreacts and grows too many new blood vessels. Those vessels ferry in immune cells that amplify inflammation. The beads don't starve the joint—they interrupt the abnormal, excessive blood flow that's driving the pain.
So you're not treating the cartilage damage itself?
No, not directly. But by reducing inflammation and the signals that trigger more vessel growth, the procedure may slow how fast the disease progresses. The blood markers suggest the joint's biology is actually changing, not just the pain.
Why is this better than just getting a knee replacement?
Replacement is major surgery. You're under general anesthesia for hours, there's a long recovery, and you're trading one problem for another—an artificial joint that will eventually wear out. This procedure takes two hours, mild sedation, and you go home the same day. It's for people who aren't ready for surgery yet, or can't have it safely.
What's the catch?
We don't know how long it lasts. The study followed people for one year. We don't know if the benefits hold at two years or five years. And we don't yet know which patients will respond best. The next step is bigger trials.
Is this going to replace knee injections?
Probably not replace them, but it could be the next step when injections stop working. It's for people with moderate to severe pain who've already tried everything else and aren't ready for surgery.
Why haven't we heard about this before?
It's not entirely new—the technique exists—but this is the first rigorous study showing it actually modifies the disease, not just masks the pain. That's the significance.